Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 558

1.

Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3 internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Bazarbachi A, Bug G, Baron F, Brissot E, Ciceri F, Abou Dalle I, Döhner H, Esteve J, Floisand Y, Giebel S, Gilleece M, Gorin NC, Jabbour E, Aljurf M, Kantarjian H, Kharfan Dabaja M, Labopin M, Lanza F, Malard F, Peric Z, Prebet T, Ravandi F, Ruggeri A, Sanz J, Schmid C, Shouval R, Spyridonidis A, Versluis J, Vey N, Savani BN, Nagler A, Mohty M.

Haematologica. 2020 Apr 2. pii: haematol.2019.243410. doi: 10.3324/haematol.2019.243410. [Epub ahead of print]

PMID:
32241850
2.

Chronic Myeloid Leukemia: 2020 Update on Diagnosis, Therapy and Monitoring.

Jabbour E, Kantarjian H.

Am J Hematol. 2020 Apr 2. doi: 10.1002/ajh.25792. [Epub ahead of print]

PMID:
32239758
3.

Evaluation and management of measurable residual disease in acute lymphoblastic leukemia.

Abou Dalle I, Jabbour E, Short NJ.

Ther Adv Hematol. 2020 Mar 6;11:2040620720910023. doi: 10.1177/2040620720910023. eCollection 2020. Review.

4.

Phase 2 Study of Hyper-CMAD with Liposomal Vincristine for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia.

Sasaki K, Kantarjian H, Wierda W, Ravandi F, Daver N, Burger J, DiNardo CD, Jain N, Short NJ, Estrov Z, Konopleva M, Ohanian M, Garcia-Manero G, Kadia T, Alvarado Y, Yilmaz M, Pierce S, Garris R, Cortes J, O'Brien S, Ingram A, Jabbour E.

Am J Hematol. 2020 Mar 14. doi: 10.1002/ajh.25784. [Epub ahead of print]

PMID:
32170867
5.

Disseminated cytomegalovirus infection with bilateral adrenal pseudotumors masquerading as recurrent hematologic malignancy.

Cabrera NL, Malek AE, Shelburne S, Taremi M, Awadh H, Francisco D, Robins A, Jabbour E, Chemaly RF.

Infection. 2020 Mar 6. doi: 10.1007/s15010-020-01404-9. [Epub ahead of print]

PMID:
32144592
6.

Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors.

Oran B, Garcia-Manero G, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO, Jabbour EJ, Mehta RS, Popat UR, Ravandi F, Alousi AM, Kadia TM, Konopleva M, DiNardo CD, Rezvani K, Shpall EJ, Sharma P, Kantarjian HM, Champlin RE, Daver N.

Cancer. 2020 Mar 3. doi: 10.1002/cncr.32796. [Epub ahead of print]

PMID:
32125707
7.

Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy.

Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F, Cortes JE, Daver N, Takahashi K, Short NJ, DiNardo CD, Jabbour E, Borthakur G, Naqvi K, Issa GC, Konopleva M, Khoury JD, Routbort M, Pierce S, Do KA, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G, Kadia TM.

Am J Hematol. 2020 Feb 28. doi: 10.1002/ajh.25769. [Epub ahead of print]

PMID:
32112433
8.

A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia.

Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F.

Leukemia. 2020 Feb 25. doi: 10.1038/s41375-020-0778-0. [Epub ahead of print] No abstract available.

PMID:
32099037
9.

Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.

Richard-Carpentier G, Jabbour E, Short NJ, Rausch CR, Savoy JM, Bose P, Yilmaz M, Jain N, Borthakur G, Ohanian M, Alvarado Y, Rytting M, Kebriaei P, Konopleva M, Kantarjian H, Ravandi F.

Clin Lymphoma Myeloma Leuk. 2019 Sep 30. pii: S2152-2650(19)31995-0. doi: 10.1016/j.clml.2019.09.608. [Epub ahead of print]

PMID:
32035785
10.

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.

Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, Naqvi K, Alvarado Y, Kadia TM, Ravandi F, Daver N, Takahashi K, Jabbour E, Borthakur G, Pemmaraju N, Konopleva M, Soltysiak KA, Pierce SR, Bueso-Ramos CE, Patel KP, Kantarjian H, Garcia-Manero G.

Blood Adv. 2020 Feb 11;4(3):482-495. doi: 10.1182/bloodadvances.2019001101.

11.

Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia.

Masarova L, Cortes JE, Patel KP, O'Brien S, Nogueras-Gonzalez GM, Konopleva M, Verstovsek S, Garcia-Manero G, Ferrajoli A, Kadia TM, Ravandi-Kashani F, Borthakur G, DellaSala S, Estrov Z, Jabbour EJ, Kantarjian HM.

Cancer. 2020 Apr 1;126(7):1448-1459. doi: 10.1002/cncr.32623. Epub 2020 Jan 30.

PMID:
31999850
12.

Long-term results of frontline dasatinib in chronic myeloid leukemia.

Maiti A, Cortes JE, Patel KP, Masarova L, Borthakur G, Ravandi F, Verstovsek S, Ferrajoli A, Estrov Z, Garcia-Manero G, Kadia TM, Nogueras-González GM, Skinner J, Poku R, DellaSala S, Luthra R, Jabbour EJ, O'Brien S, Kantarjian HM.

Cancer. 2020 Apr 1;126(7):1502-1511. doi: 10.1002/cncr.32627. Epub 2020 Jan 30.

PMID:
31999839
13.

FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.

Antar AI, Otrock ZK, Jabbour E, Mohty M, Bazarbachi A.

Leukemia. 2020 Mar;34(3):682-696. doi: 10.1038/s41375-019-0694-3. Epub 2020 Jan 9. Review.

PMID:
31919472
14.

Treatment-free remission in chronic myeloid leukemia.

Molica M, Naqvi K, Cortes JE, Paul S, Kadia TM, Breccia M, Kantarjian H, Jabbour EJ.

Clin Adv Hematol Oncol. 2019 Dec;17(12):686-696.

PMID:
31851157
15.

The face of remission induction.

Paul S, Rausch CR, Jabbour EJ.

Br J Haematol. 2020 Jan;188(1):101-115. doi: 10.1111/bjh.16353. Epub 2019 Dec 12. Review.

PMID:
31828798
16.

Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management.

Rausch CR, Jabbour EJ, Kantarjian HM, Kadia TM.

Cancer. 2020 Mar 15;126(6):1152-1160. doi: 10.1002/cncr.32606. Epub 2019 Dec 3. No abstract available.

PMID:
31794095
17.

Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.

Jabbour E, Gökbuget N, Advani A, Stelljes M, Stock W, Liedtke M, Martinelli G, O'Brien S, Wang T, Laird AD, Vandendries E, Neuhof A, Nguyen K, Dakappagari N, DeAngelo DJ, Kantarjian H.

Leuk Res. 2020 Jan;88:106283. doi: 10.1016/j.leukres.2019.106283. Epub 2019 Nov 25.

18.

The role of cladribine in acute myeloid leukemia: an old drug up to new tricks.

Molica M, Breccia M, Capria S, Trisolini S, Foa R, Jabbour E, Kadia TM.

Leuk Lymphoma. 2020 Mar;61(3):536-545. doi: 10.1080/10428194.2019.1672060. Epub 2019 Nov 22.

PMID:
31752577
19.

Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.

Sasaki K, Kanagal-Shamanna R, Montalban-Bravo G, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Patel K, Soltysiak KA, Cortes J, Kantarjian HM, Garcia-Manero G.

Cancer. 2020 Feb 15;126(4):765-774. doi: 10.1002/cncr.32566. Epub 2019 Nov 19.

PMID:
31742675
20.

Complexity of chronic-phase CML management after failing a second-generation TKI.

El Fakih R, Chaudhri N, Alfraih F, Rausch CR, Naqvi K, Jabbour E.

Leuk Lymphoma. 2020 Apr;61(4):776-787. doi: 10.1080/10428194.2019.1691196. Epub 2019 Nov 18.

PMID:
31739705
21.

The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival.

Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour E.

Am J Hematol. 2020 Feb;95(2):144-150. doi: 10.1002/ajh.25671. Epub 2019 Nov 19.

PMID:
31682008
22.

Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation.

Srour SA, Saliba RM, Bittencourt MCB, Perez JMR, Kongtim P, Alousi A, Al-Atrash G, Olson A, Betul O, Mehta R, Popat U, Hosing C, Bashir Q, Khouri I, Kebriaei P, Masarova L, Short N, Jabbour E, Daver N, Konopleva M, Ravandi F, Kantarjian H, Champlin RE, Ciurea SO.

Am J Hematol. 2019 Dec;94(12):1382-1387. doi: 10.1002/ajh.25647. Epub 2019 Oct 21.

PMID:
31595538
23.

Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.

Abou Dalle I, Kantarjian HM, Short NJ, Konopleva M, Jain N, Garcia-Manero G, Garris R, Qiao W, Cortes JE, O'Brien S, Kebriaei P, Kadia T, Jabbour E, Ravandi F.

Am J Hematol. 2019 Dec;94(12):1388-1395. doi: 10.1002/ajh.25648. Epub 2019 Oct 21.

PMID:
31595534
24.

Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia.

Alfayez M, Richard-Carpentier G, Jabbour E, Vishnu P, Naqvi K, Sasaki K, Cortes J, Pemmaraju N.

Br J Haematol. 2019 Nov;187(4):543-545. doi: 10.1111/bjh.16245. Epub 2019 Oct 4. No abstract available.

PMID:
31584727
25.

Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia.

Rafei H, Kantarjian HM, Jabbour EJ.

Br J Haematol. 2020 Jan;188(2):207-223. doi: 10.1111/bjh.16207. Epub 2019 Sep 30. Review.

PMID:
31566728
26.

Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.

Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM.

Cancer. 2020 Jan 1;126(1):67-75. doi: 10.1002/cncr.32504. Epub 2019 Sep 25.

PMID:
31553487
27.

Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States.

Abou Dalle I, Kantarjian H, Burger J, Estrov Z, Ohanian M, Verstovsek S, Ravandi F, Borthakur G, Garcia-Manero G, Jabbour E, Cortes J.

Cancer Med. 2019 Nov;8(15):6559-6565. doi: 10.1002/cam4.2545. Epub 2019 Sep 10.

28.

Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study.

Jabbour EJ, Gökbuget N, Kantarjian HM, Thomas X, Larson RA, Yoon SS, Ghobadi A, Topp MS, Tran Q, Franklin JL, Forman SJ, Stein AS.

Cancer. 2019 Dec 1;125(23):4181-4192. doi: 10.1002/cncr.32335. Epub 2019 Aug 21.

PMID:
31433496
29.

Maintenance therapy in AML: The past, the present and the future.

Molica M, Breccia M, Foa R, Jabbour E, Kadia TM.

Am J Hematol. 2019 Nov;94(11):1254-1265. doi: 10.1002/ajh.25620. Epub 2019 Sep 11. Review.

PMID:
31429099
30.

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.

Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM.

Lancet Haematol. 2019 Sep;6(9):e480-e488. doi: 10.1016/S2352-3026(19)30114-0. Epub 2019 Aug 7.

PMID:
31400961
31.

Therapy Options in Treating Acute Lymphoblastic Leukemia in Adults.

Jabbour E.

Oncology (Williston Park). 2019 Jul 16;33(7). pii: 629385. No abstract available.

32.

Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.

Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver N, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F.

Cancer. 2019 Nov 1;125(21):3755-3766. doi: 10.1002/cncr.32387. Epub 2019 Jul 16.

PMID:
31310323
33.

SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia.

Paul S, Rausch CR, Welch MA, Kantarjian HM, Jabbour EJ.

Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):471-479. doi: 10.1016/j.clml.2019.06.011. Epub 2019 Jul 3. Review.

PMID:
31307896
34.

Reply to Mini-HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope?

Sasaki K, Kantarjian HM, Jabbour EJ.

Cancer. 2019 Nov 1;125(21):3891-3892. doi: 10.1002/cncr.32385. Epub 2019 Jul 10. No abstract available.

PMID:
31291004
35.

Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series.

Rafei H, Jabbour EJ, Kantarjian H, Sinicrope KD, Kamiya-Matsuoka C, Mehta RS, Daver NG, Kadia TM, Naqvi K, Cortes J, Konopleva M.

Leuk Lymphoma. 2019 Dec;60(13):3292-3295. doi: 10.1080/10428194.2019.1633635. Epub 2019 Jun 27. No abstract available.

PMID:
31246142
36.

Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia.

Guerra VA, Jabbour EJ, Ravandi F, Kantarjian H, Short NJ.

Ther Adv Hematol. 2019 May 19;10:2040620719849496. doi: 10.1177/2040620719849496. eCollection 2019. Review.

37.

Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia.

Chamoun K, Kantarjian HM, Wang X, Naqvi K, Aung F, Garcia-Manero G, Borthakur G, Jabbour E, Kadia T, Daver N, DiNardo CD, Jain N, Konopleva M, Cortes J, Ravandi F, Yilmaz M.

Cancer. 2019 Sep 15;125(18):3219-3224. doi: 10.1002/cncr.32196. Epub 2019 May 31.

PMID:
31150121
38.

Ibrutinib and Venetoclax for First-Line Treatment of CLL.

Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W.

N Engl J Med. 2019 May 30;380(22):2095-2103. doi: 10.1056/NEJMoa1900574.

PMID:
31141631
39.

Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy.

Boddu P, Jain P, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jabbour E, Cortes J, Kantarjian H.

Leuk Lymphoma. 2019 Dec;60(13):3172-3180. doi: 10.1080/10428194.2019.1617862. Epub 2019 May 24.

PMID:
31125272
40.

Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models.

Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, Zhao Y, Kim E, Rahmani M, Mak DH, Jin SS, Chen J, Phillips DC, Koller PB, Jacamo R, Burks JK, DiNardo C, Daver N, Jabbour E, Wang J, Kantarjian HM, Andreeff M, Grant S, Leverson JD, Sampath D, Konopleva M.

Haematologica. 2020 Mar;105(3):697-707. doi: 10.3324/haematol.2018.205534. Epub 2019 May 23.

41.

Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy.

Khogeer H, Rahman H, Jain N, Angelova EA, Yang H, Quesada A, Ok CY, Sui D, Wei P, Al Fattani A, Pierce S, Loghavi S, Lamb A, Hu P, Thakral B, Kanagal-Shamanna R, Jorgensen JL, Jabbour EJ, Kantarjian HM, Medeiros LJ, Khoury JD.

Br J Haematol. 2019 Aug;186(4):538-548. doi: 10.1111/bjh.15960. Epub 2019 May 22.

PMID:
31115909
42.

Recent advances in the treatment of acute lymphoblastic leukemia.

Rafei H, Kantarjian HM, Jabbour EJ.

Leuk Lymphoma. 2019 Nov;60(11):2606-2621. doi: 10.1080/10428194.2019.1605071. Epub 2019 May 16.

PMID:
31092071
43.

Economic modeling to evaluate the impact of chronic myeloid leukemia therapy management on the oncology care model in the US.

Jabbour EJ, Mendiola MF, Lingohr-Smith M, Lin J, Makenbaeva D.

J Med Econ. 2019 Nov;22(11):1113-1118. doi: 10.1080/13696998.2019.1618316. Epub 2019 May 31.

PMID:
31074658
44.

Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.

Garcia-Manero G, Roboz G, Walsh K, Kantarjian H, Ritchie E, Kropf P, O'Connell C, Tibes R, Lunin S, Rosenblat T, Yee K, Stock W, Griffiths E, Mace J, Podoltsev N, Berdeja J, Jabbour E, Issa JJ, Hao Y, Keer HN, Azab M, Savona MR.

Lancet Haematol. 2019 Jun;6(6):e317-e327. doi: 10.1016/S2352-3026(19)30029-8. Epub 2019 May 3.

PMID:
31060979
45.

Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.

Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Cortes J, Issa GC, Jacob J, Kwari M, Thompson P, Garris R, Pemmaraju N, Yilmaz M, O'Brien SM, Kantarjian HM.

Cancer. 2019 Aug 1;125(15):2579-2586. doi: 10.1002/cncr.32139. Epub 2019 Apr 15.

PMID:
30985931
46.

Development of a symptom assessment in patients with myelofibrosis: qualitative study findings.

Mesa RA, Su Y, Woolfson A, Prchal JT, Turnbull K, Jabbour E, Scherber R, Shields AL, Krohe M, Ojo F, Pompilus F, Cappelleri JC, Harrison C.

Health Qual Life Outcomes. 2019 Apr 11;17(1):61. doi: 10.1186/s12955-019-1121-1.

47.

Treatment of relapsed/refractory acute lymphoblastic leukemia.

Paul S, Rausch CR, Nasnas PE, Kantarjian H, Jabbour EJ.

Clin Adv Hematol Oncol. 2019 Mar;17(3):166-175. Review.

PMID:
30969955
48.

Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.

Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gökbuget N, O'Brien SM, Jabbour E, Wang T, Liang White J, Sleight B, Vandendries E, Advani AS.

Cancer. 2019 Jul 15;125(14):2474-2487. doi: 10.1002/cncr.32116. Epub 2019 Mar 28.

49.

Relapsed B-acute lymphoblastic leukemia with aberrant myeloperoxidase expression following CAR T-cell therapy: A diagnostic challenge.

Li N, Wang SA, Lin P, Jabbour E, Thompson P, Chen Z, Li S, Xu J, You MJ, Bueso-Ramos CE, Medeiros LJ, Yin CC.

Am J Hematol. 2019 Sep;94(9):1049-1051. doi: 10.1002/ajh.25478. Epub 2019 Apr 13. No abstract available.

PMID:
30916805
50.

Analysis of CAST in 9 Lebanese hospitals between 2008 and 2017.

Fares J, Jabbour E, Haidar A, Souidan H, Soboh I, Massaad N, Dandachi I, Moghnieh R, Samaha R, Daoud Z.

J Infect Public Health. 2019 Sep - Oct;12(5):650-655. doi: 10.1016/j.jiph.2019.03.002. Epub 2019 Mar 20.

Supplemental Content

Loading ...
Support Center